Metronidazole: Nitroimidazole Antibiotic and OAT3 Inhibitor for Advanced Research

Executive Summary: Metronidazole is a nitroimidazole antibiotic (C6H9N3O3, MW: 171.15) that targets anaerobic bacteria and protozoa with high specificity (APExBIO B1976). It acts as a potent Organic Anion Transporter 3 (OAT3) inhibitor (IC50: 6.51 ± 0.99 μM, Ki: 6.48 μM), influencing drug influx such as methotrexate (Yan et al., 2025). With high purity (≥98%) and robust solubility (water ≥3.13 mg/mL, ethanol ≥11.54 mg/mL, DMSO ≥8.55 mg/mL, all with ultrasonic assistance), it is suited for research into antibiotic action, transporter pharmacology, and microbiota-immune interactions. The compound should be stored at -20°C; solutions are for short-term use. APExBIO supplies this product for scientific research only, not for diagnostic or clinical application.

Biological Rationale

Metronidazole's core utility stems from its dual role as a nitroimidazole antibiotic and an OAT3 inhibitor. It is widely used to study both anaerobic bacterial and protozoal models, as well as cellular influx mechanisms mediated by organic anion transporters. The compound’s ability to inhibit OAT3 and OATP1A2 enables interrogation of drug-drug interaction scenarios, especially where transporter-mediated uptake is relevant (see extended discussion here; this article updates the molecular mechanism focus by integrating latest IC50 data). Research on immune-microbiota links, such as Th1/Th2 balance and short-chain fatty acids (SCFAs), increasingly utilizes antibiotics like Metronidazole to shape experimental models (Yan et al., 2025).

Mechanism of Action of Metronidazole

Metronidazole exerts bactericidal effects by entering anaerobic cells, where its nitro group is reduced to reactive intermediates that disrupt DNA synthesis and integrity. This specificity restricts its action to anaerobic bacteria and protozoa, as aerobic organisms cannot efficiently reduce the drug. In parallel, Metronidazole inhibits OAT3-mediated transport, as measured by an IC50 of 6.51 ± 0.99 μM and Ki of 6.48 μM, blocking cellular uptake of critical substrates like methotrexate in experimental settings (APExBIO datasheet). This dual mechanism supports both pathogen suppression and transporter pharmacology research. For an in-depth translational perspective, this article emphasizes clinical translation; here, we focus on quantitative transporter inhibition parameters.

Evidence & Benchmarks

• Metronidazole inhibits OAT3 with an IC50 of 6.51 ± 0.99 μM, confirmed in cellular uptake assays (APExBIO).
• As a nitroimidazole antibiotic, it selectively targets anaerobic bacteria and protozoa via DNA disruption (Yan et al., 2025).
• Metronidazole modulates transporter-mediated drug influx, including methotrexate, via OAT3 and OATP1A2 inhibition (contrast: this article highlights broader immune-microbiota impacts; here, strict transporter data are foregrounded).
• Solubility benchmarks: ≥11.54 mg/mL in ethanol, ≥3.13 mg/mL in water, ≥8.55 mg/mL in DMSO, all with ultrasonic assistance (APExBIO).
• Th1/Th2 immune balance and gut microbiota composition are affected by antibiotic-driven flora modulation; Metronidazole is frequently used as a reference compound in these models (Yan et al., 2025).

Applications, Limits & Misconceptions

Metronidazole is a reference agent in studies on:

• Antibiotic action on anaerobic bacteria and protozoa.
• Organic anion transporter (OAT3, OATP1A2) pharmacology, including drug-drug interaction assays.
• Microbiota-immune axis modulation, such as Th1/Th2 signaling and SCFA profiles.
• Experimental workflows in drug screening and transporter inhibition benchmarking.

For an advanced discussion of Metronidazole’s role in translational research, this article explores immune-microbiota crosstalk; here, precise solubility and IC50/transport inhibition data are uniquely detailed.

Common Pitfalls or Misconceptions

• Metronidazole is not effective against aerobic bacteria due to lack of nitro group reduction in those organisms.
• It should not be used as a general transporter inhibitor; its specificity is strongest for OAT3, with limited data for other OAT isoforms.
• Solutions are stable only for short-term use; degradation may occur if stored above -20°C or for extended periods.
• This compound is not intended for diagnostic or clinical applications; for research use only as supplied by APExBIO.
• OAT3 inhibition may not fully predict in vivo drug-drug interaction risk without appropriate pharmacokinetic modeling.

Workflow Integration & Parameters

Preparation: Dissolve Metronidazole at ≥3.13 mg/mL in water, ≥11.54 mg/mL in ethanol, or ≥8.55 mg/mL in DMSO, using ultrasonic assistance. For transporter assays, solutions should be freshly prepared and kept at -20°C until use.

Assay Integration: OAT3 inhibition assays typically employ concentrations at or near IC50 (6.51 μM) for benchmarking. For microbiota studies, dosing should be adjusted per animal model and experimental design (Yan et al., 2025).

For further insights into dual-action mechanisms or integration with immune signaling readouts, see this review, which offers broader context; this article uniquely focuses on parameterization and supplier specifications.

Conclusion & Outlook

Metronidazole (APExBIO B1976) is a validated tool for investigating nitroimidazole antibiotic activity and OAT3-mediated transporter pharmacology. Its quantitative benchmarks, high purity, and detailed solubility make it suited for controlled experimental workflows in antibiotic, transporter, and immune-microbiota research. Future models may leverage Metronidazole for even more precise dissection of gut-immune-drug interactions, building on established transporter inhibition data and microbiota modulation findings (Yan et al., 2025).